Gilead Sciences (GILD) built its foundation on HIV treatment. Biktarvy alone accounted for $14.3 billion of the company's $29 ...
Al Jazeera on MSN
HIV prevention drug hailed as breakthrough, but who gets access?
Lenacapavir, a twice-a-year injection could transform HIV prevention, but it will not be available to all.
In an HIV prevention trial, an antibody blocked the viruses most vulnerable to it, but others broke through. Now researchers have uncovered how HIV evolved after those infections—and why the amount of ...
On National Latinx AIDS Awareness Day, experts outline HIV prevention gaps in Hispanic communities and how payers can ease ...
A new review in Virology Journal examines how simplified and long-acting antiretroviral regimens reduce treatment burden ...
Add Yahoo as a preferred source to see more of our stories on Google. Despite highly effective HIV prevention drugs on the market, only a fraction of those at risk in the U.S. are taking them — or ...
The landscape of HIV prevention has undergone a profound transformation with significant advancements in medical interventions and a deeper understanding of how the virus spreads. These developments ...
A new study published in BMJ Open proposes a couples-based intervention to help prevent HIV acquisition among pregnant and ...
NBC 10 WJAR is the news, sports and weather leader for Providence, Rhode Island and surrounding communities, including ...
Created by Atlanta-based agency Majori ty as part of Gilead Sciences’ Care for the Culture platform, the “Ahorita Mismo” ...
Featured individuals were compensated for their time. Sex should feel good, pleasurable, and uninhibited. But protecting your sexual health is still an important part of the experience. HIV prevention ...
A sweeping survey of more than 4,000 university students in southwest China has revealed a troubling mismatch at the heart of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results